There are currently 145 active clinical trials seeking participants for Pancreatic Cancer research studies. The states with the highest number of trials for Pancreatic Cancer participants are California, New York, Illinois and Texas.
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT05708950
Recruiting
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? Participants in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: UCLA Health (Santa Monica Cancer Care), Santa Monica, California +5 locations
Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Register for Updates
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
NCT05057715
Recruiting
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pancreatic Cancer, Serous Ovarian Cancer
Register for Updates
PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
NCT05697198
Recruiting
The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next generation sequencing of time-matched or archival tissue specimens from individuals with advanced solid tumors. Examples of locally advanced and metastatic tumors include stage III and IV cancers (ex. lung, breast, all gastrointestinal malignancies, all gynecologic mali... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Clinical Site, Fort Payne, Alabama +7 locations
Conditions: Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer, Stomach Cancer, Esophageal Cancer, Pancreatic Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Rhabdomyosarcoma, Prostate Cancer
Register for Updates
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT04150042
Recruiting
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed fo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic, Breast Cancer Stage IV, Pancreatic Cancer Stage IV, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Adenocarcinoma of the Breast, PALB2 Gene Mutation
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835
Recruiting
This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with locally advanced and/or metastatic solid tumours. In Phase Ia, using a 3+3 design, escalating doses of AVA6000 will be administered to patients with a range of solid tumour types to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). In Phase 1b, the selected RP2D dose w... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2023
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +7 locations
Conditions: Pancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Ovarian Cancer, Bladder Cancer, Cancer of Unknown Primary Site, Oesophageal Cancer, Prostate Cancer, Biliary Tract Cancer
Register for Updates
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
NCT04426669
Recruiting
A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Gastro-Intestinal (GI) Cancer.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/02/2023
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal, Gastrointestinal Cancer, Colo-rectal Cancer, Pancreatic Cancer, Gall Bladder Cancer, Colon Cancer, Esophageal Cancer, Stomach Cancer
Register for Updates
U01-Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer
NCT03886571
Recruiting
This is an observational, biospecimen collection protocol to develop a bank of pancreatic cancer tissue and normal tissue.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2023
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Pancreatic Cancer
Register for Updates
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
NCT05462314
Recruiting
The primary objective of this prospective observational study is to characterize the gut and oral microbiome as well as the whole blood transcriptome in gastrointestinal cancer patients and correlate these findings with cancer type, treatment efficacy and toxicity. Participants will be recruited from existing clinical sites only, no additional clinical sites are needed.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/13/2023
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Gastrointestinal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Rectal Cancer, Liver Cancer, Biliary Cancer
Register for Updates
New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)
NCT05188586
Recruiting
Bluestar Genomics has developed a non-invasive test that aids in detection of occult pancreatic cancer in patients with new onset type II diabetes (NOD) who are 50 years old or older. The purpose of this study is to evaluate the performance of Bluestar Genomics early-detection pancreatic cancer test in a clinical setting. The study is prospective, longitudinal and interventional; tests will be ordered and results returned to site-investigators. If the test returns a pancreatic cancer signal "det... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
12/06/2022
Locations: Headlands Research - Scottsdale - PPDS, Scottsdale, Arizona +4 locations
Conditions: Pancreatic Cancer
Register for Updates
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT04678648
Recruiting
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2022
Locations: University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California +5 locations
Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Register for Updates
Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
NCT05535894
Recruiting
This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Shailendra Singh, Morgantown, West Virginia
Conditions: Pancreatic Cancer
Register for Updates
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT03104439
Recruiting
This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. The interventions involved in this study are: Nivolumab Ipilimumab Radiation Therapy
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts general Hospital, Boston, Massachusetts
Conditions: Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer
Register for Updates